" /> Camrelizumab - CISMeF





Preferred Label : Camrelizumab;

NCIt synonyms : Carrizumab; AiRuiKa (TM);

NCIt definition : A monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1,) with immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-1 monoclonal antibody SHR-1210 binds to and blocks the binding of PD-1, expressed on activated T-lymphocytes, B-cells and natural killer (NK) cells, to its ligands programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen presenting cells (APCs). This prevents the activation of PD-1 and its downstream signaling pathways. This restores immune function through the activation of cytotoxic T-lymphocytes (CTLs) and cell-mediated immune responses against tumor cells or pathogens. Activated PD-1 negatively regulates T-cell activation and plays a key role in tumor evasion from host immunity.;

UNII : 73096E137E;

CAS number : 1798286-48-2; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 1798286-48-2 alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo G-SRS /a ;

Drug name : AiRuiKa;

Molecule name : SHR-1210; HR-301210; SHR 1210;

NCI Metathesaurus CUI : CL498210;

Codes from synonyms : 14742;

Details


Keyword's position in hierarchy(ies) : arborescence

You can consult :


Nous contacter.
12/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.